Opperbas Holding

Opperbas Holding B.V. is a private investment and holding company based in Utrecht, Netherlands, primarily serving as the investment vehicle for Erik van den Berg, a prominent executive in the European biotechnology sector. The company is most notably recognized as a significant shareholder and founding-related entity for Lava Therapeutics N.V. (NASDAQ: LAVA), a clinical-stage immuno-oncology company developing bispecific gamma-delta T cell engagers. Additionally, Opperbas Holding has been instrumental in the strategic management and financing of AM-Pharma, a developer of recombinant human alkaline phosphatase for severe inflammatory conditions. While the entity does not conduct independent research and development or maintain a proprietary drug pipeline, it plays a critical role in the governance and capitalization of its portfolio companies. For a biotech analyst, Opperbas Holding is a key insider entity within the Dutch life sciences ecosystem, closely linked to the leadership of major clinical-stage biopharmaceutical firms.